MPS Limited operates as an AI-first global knowledge solutions provider, delivering content, platform, and learning services across Research, Education, and Corporate Learning segments. The company sits at the verification layer of the academic and enterprise publishing value chain, converting specialized domain expertise into trusted, peer-reviewed outputs. Operating in a niche with high switching costs and mission-critical workflows, MPS serves over 841 clients and holds a 0.5% share of its total serviceable market. The company's economics are exceptional, with Q1 FY27 consolidated EBITDA margins expanding to 34.3% from 27.0% a year ago, and its Research Solutions segment posting a 45.1% EBITDA margin. This margin level, sustained above 30% at the consolidated level, indicates a business possessing significant pricing power and structural advantages rather than a commoditized content factory.
The durability of these economics stems from deep integration into high-stakes knowledge workflows where accuracy cannot be compromised. Unbound Medicine, acquired in February 2026 for USD 16.5 million, illustrates this barrier clearly, embedding its platforms into over 480 institutions with a 97% retention rate. Switching costs are prohibitive because the platform provides legally indemnified, evidence-based clinical intelligence, a trust gap that generic large language models cannot bridge. Furthermore, MPS leverages a 200-engineer AI R&D engine to compound capabilities across segments at minimal marginal cost. The company's pre-acceptance peer review services demonstrate a 52% manuscript acceptance rate against a 32% industry baseline, creating a measurable performance moat that locks in institutional clients and drives vendor consolidation in a fragmented market.
The critical inflection over the next 18 to 24 months centers on scaling the Unbound Medicine integration and realizing AI-driven operating leverage across the portfolio. By FY28, management targets approximately INR 1,500 crores in revenue and INR 450 crores in EBITDA. Unbound Medicine, currently generating a monthly run rate of USD 800,000 at an 18% to 20% EBITDA margin, is guided to reach USD 750,000 to USD 950,000 per month in FY27 while exiting the year with a 25% to 30% EBITDA margin. Concurrently, the Education segment, growing 42.2% year-over-year in Q1 FY27 to INR 73.41 crores, will scale its accessibility business and cross-sell immersive solutions into Unbound's institutional base. Corporate Learning, currently resetting with a 25.3% Q1 FY27 EBITDA margin, is expected to return to organic growth and reach a 30% steady-state margin by FY28, completing its integration into the unified Liberate Global brand.
Management's walk-talk alignment demonstrates credible execution against stated targets. In November 2025, leadership outlined a plan to deploy INR 300 to 400 crores in acquisitions over 12 to 18 months using internal cash and debt, deliberately avoiding equity dilution. The Unbound acquisition closed in February 2026, funded entirely with debt against a comfortable balance sheet holding INR 138.02 crores in cash against INR 37.63 crores in borrowings by Q1 FY27. Earlier promises to surpass an FY26 EPS of INR 100 were reiterated, though trailing metrics showed this was largely baked into the run-rate. Guidance has been consistently held rather than raised, with the FY27 EBITDA target of INR 300 crores treated as a floor and the FY28 revenue vision of INR 1,500 crores remaining intact, supported by monthly cash generation of INR 15 to 18 crores.
The quantified earnings path requires the consolidated EBITDA margin to sustain in the mid-30s while Unbound Medicine scales from a 15% entry margin to a 25% to 30% exit margin by the close of FY27. For this trajectory to hold, the deliberate downsizing of the AJE B2C revenue base must stabilize without further margin drag, and Corporate Learning must accelerate from its current 6.9% organic growth to approach the 12% market growth rate. The single most important watchpoint is the Unbound Medicine synergy timeline, which management has not yet committed to as they learn the renewal cycle. If Unbound margins fail to scale toward 25% by the end of FY27, or if Corporate Learning continues to lag market growth, the path to INR 450 crores in EBITDA by FY28 relies heavily on finding and integrating additional acquisitions from the current 35-company pipeline without overleveraging the balance sheet.
companyname: MPS Limited ticker: MPSLTD sector: Content, Platform, and Learning Solutions for Education, Research, and Corporate Markets MPS Limited is a B2B provider of content, platform, and learning solutions for the research, education, and corporate training markets. It started as Macmillan Publishing Solutions in 1970, changed ownership in 2012, and has since built scale through 15 acquisitions in 12 years. The company employs over 3,000 professionals across five delivery centers in India...
Read the full report →margin expansion, geographic expansion, acquisition inorganic
FY’27 EBITDA guided at INR 300 crores, implying a 3-year EBITDA CAGR of approximately 21% from FY’24 to FY’27 driven by Unbound integration, research operating leverage, and corporate learning margin expansion
Guidance no_datamixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for MPS Limited and 4,900+ companies.
5-day free pass. No card required.